1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Urogen's Novel Formula For Urothelial Cancer Presents Unique Commercial Challenges

 
• By Jessica Merrill

The company expects to launch a proprietary gel formulation of chemo drug mitomycin for urothelial cancer in the first half of 2020.

Passenger-plane

UroGen Pharma Ltd. is on track to launch its first drug, a novel gel formulation of the chemotherapy drug mitomycin for low-grade upper tract urothelial cancer (LG UTUC), in the first half of 2020 and is ramping up its commercial plans for the launch, which could face some unique challenges.

The company's management – including chairman Arie Belldegrun, the former Kite Pharma Inc. founder, and CEO Elizabeth Barrett –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

More from Therapy Areas